CMV reactivation after allo-HCT has been associated with a reduced relapse risk in AML [10,11], and this protection has been linked to expansions of adaptive “memory-like” NK phenotypes, including NKG2C+ subsets [12,13]. This evidence concerns the gene KLRC2 and acute myeloid leukemia.